Agreement - February 23, 2026
Affibody signs Letter of Intent with SHINE Technologies
A Letter of Intent (LOI) has been signed with SHINE Technologies as an additional supplier of non-carrier-added Lutetium-177 (n.c.a. Lu-177).
Agreement - February 16, 2026
Ribocure in global licensing agreement
Suzhou Ribo Life Science and its Swedish subsidiary Ribocure Pharmaceuticals have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Agreement - January 30, 2026
Bavarian Nordic signs distribution agreement with Eurofarma
Bavarian Nordic has announced an agreement with Eurofarma, granting them exclusive rights to sell and distribute Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, in Brazil.
Agreement - January 21, 2026
Sigrid Therapeutics enters collaboration to commercialize SiPore
The company has entered into an exclusive global licensing and research collaboration with a multinational consumer health company to expand the SiPore technology platform into consumer oral health through a partner-led approach.
Agreement - January 20, 2026
OnDosis enters collaboration with Diamond Therapeutics
The two companies have entered into an agreement regarding the use of the OnDosis drug delivery platform, the Dosage Manager, in Diamond’s psychoactive low-dose psilocybin programs.
Agreement - January 4, 2026
Orexo in agreement with Dexcel to divest US rights to Zubsolv
The company has signed an agreement with Dexcel Pharma USA, to divest the full rights to Zubsolv (buprenorphine/naloxone) sublingual tablet CIII, for the treatment of opioid use disorder, in the US.
